Author(s)

Jieke Tang¹, Zhao Zhong^1*#, Fangchao Chen², Jinyong Liu^2*

Affiliation(s)

¹ Department of Anesthesiology, First Affiliated Hospital of Jinan University, Guangzhou, China

² Guangzhou First People’s Hospital, the Second Affiliated Hospital of South China University of Technology, Guangzhou, China

Corresponding Author

Zhao Zhong, Jinyong Liu

ABSTRACT

In this study, we aimed to study the selectivity of therapeutic targets in cancer chemotherapy through a new targeting peptide. Peptide specifically binding to human lung adenocarcinoma was identified through a NCI-H1299 subcutaneous xenograft model, results showed that RGD was concentrated mainly in the tumor while less accumulation of fluorescence in the tumor was found in control group animals. Ability of RGD to target human lung cancer tissue in vitro was investigated through tissue microarray, results show that a 7-fold higher detection rate of [RGD]^FITC was achieved compared with the control group, indicating the potential of RGD as carriers for targeted cancer therapy drug. In conclusion, RGD is specifically targeted to human lung adenocarcinoma xenografted and had high specifically and affinity with lung cancer tissues, it might be an efficient method to increase the selectivity of therapeutic targets in cancer chemotherapy.

KEYWORDS

Lung Cancer; Polypeptide; arginine-glycine-aspartic acid

CITE THIS PAPER

Jieke Tang, Zhao Zhong, Fangchao Chen, Jinyong Liu. Study on targeting of lung cancer with polypeptide RGD. Acta Translational Medicine. 2018, 1(1): 13-18.

REFERENCES

[1] W. Chen, R. Zheng, P. D. Baade, et al. Cancer statistics in China, 2015, CA Cancer J Clin, Vol. 43(2016) No.2, p.115-132.
[2] C. E. DeSantis, C. C. Lin, A. B. Mariotto, et al. Cancer treatment and survivorship statistics, 2014, CA Cancer J Clin, Vol. 64(2014) No.4, p.252-271.
[3] V. T. DeVita, E. Chu. A history of cancer chemotherapy, Cancer Res, Vol. 68(2008) No.21, p.8643-8653.
[4] S. Vishnu, R. B. Jayesh, K. G. Santosh. Modeling the cytotoxicity of cisplatin, Ind Eng Chem Res, Vol. 50(2011) No.23, p.86-98.
[5] V. Cepeda, M. A. Fuertes, J. Castilla, et al. Biochemical Mechanisms of Cisplatin Cytotoxicity, Anticancer Agents Med Chem, Vol. 7(2007) No.1, p.3-18.
[6] Hynes R. O. Integrins: bidirectional, allosteric signaling machines, Cell, Vol. 110(2002) No.6, p.673-687.
[7] T. Kai, R. M. Schiffelers, G. Molema, et al. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature, Drug Resist Updat, Vol. 8(2005) No.6, p.381-402.
[8] R. N. Prajapati, P. K. Tekade, U. Gupta, et al. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam, Mol Pharm, Vol. 6(2009) No.3, p.940-950.
[9] L. R. Douglas, J. R. Nancy, J. D. Barry. A cryoprotection method that facilitates cutting frozen sections of whole monkey brains for histological and histochemical processing without freezing artifact, J Histochem Cytochem, Vol. 34(1986) No.10, p.1301-1315.
[10] L. Gentilucci, R. De Marco, L. Cerisoli. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization, Curr Pharm Des, Vol. 16(2010) No.28, p.3185-3203.
[11] Carolyn F. D., Michael A. N., Maibritt T. N., et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects, Diabetes, Vol. 44(1995) No.28, p.1126-1131.
[12] M. F. Powell, T. Stewart, L. J. Otvos, et al. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum, Pharm Res, Vol. 10(1993) No.9, p.1268-1273.